Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia

NAUnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 20, 2022

Primary Completion Date

November 20, 2023

Study Completion Date

June 20, 2024

Conditions
Dialysis; ComplicationsHeparin-induced ThrombocytopeniaChronic Renal Failure
Interventions
PROCEDURE

Hydrolink NV membrane

"patient dialysis on a Hydrolink-NV® membrane with an anticoagulant dose decrease protocol.~Period 1 : conventional membrane with his usual anticoagulant for 4 weeks. Period 2 : Hydrolink-NV® membrane with maintenance of the previous doses of Orgaran® Period 3 : Hydrolink-NV® membrane with a decrease in Orgaran® Period 4 : Hydrolink-NV® membrane with the minimum effective dose of Orgaran® or without Orgaran® for a period of 3 months (M4, M5, M6)."

Trial Locations (1)

91480

Hôpital Privé Claude Galien, Quincy-sous-Sénart

All Listed Sponsors
collaborator

European Clinical Trial Experts Network

OTHER

lead

Ramsay Générale de Santé

OTHER